Data Supplement
- Supplemental Data -
Supplementary Table 1 - Demographic and clinical details of 28 human intestine samples. Information on age, gender, medical history is provided.
Supplementary Table 2 - Overview of the transition schedules and the respective ions selected for the native and isotope labelled peptides used for quantification of drugmetabolising enzymes.
Supplementary Table 3 - Overview of the transition schedules and the respective ions selected for the native and isotope labelled peptides used for quantification of transporters.
Supplementary Table 4 - Real time PCR primers (forward and reverse) for human intestinal transporters.
Supplementary Table 5 - Comparison of the abundance of drug-metabolising enzymes quantified in the present study with data reported in the literature.
Supplementary Table 6 - Comparison of the abundance of drug transporters quantified in the present study with data reported in the literature.
Supplementary Figure 1 - Experimental workflow. QconCAT technology was applied to quantify cytochrome P450 (CYP), uridine 5'-diphospho-glucuronosyltransferase (UGT) and transporters in 16 human intestine (HI) crude membrane samples.
Supplementary Figure 2 - Representative examples of co-elution profiles of selected ABC transporters, the membrane marker (Na+/K+ ATPase) and HPT1, a cell-cell adhesion molecule which also functions as a proton-dependent oligopeptide transporter in the GI tract. Profiles were captured using Skyline.
Supplementary Figure 3 - Representative examples of co-elution profiles of selected SLC transporters. Profiles were captured using Skyline.
Supplementary References